Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Feb 20;9(1):2375.
doi: 10.1038/s41598-019-38956-2.

Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis

Lana C Pinto  1 , Mariana R Falcetta  2 , Dimitris V Rados  2 , Cristiane B Leitão  2 , Jorge L Gross  2
Affiliations
Meta-Analysis

Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis

Lana C Pinto et al. Sci Rep. .

Abstract

We aimed to assess if GLP-1 agonists are associated with pancreatic cancer. Systematic review and meta-analysis of randomized trials with GLP-1 agonists as an intervention was performed. Trial sequential analysis (TSA) was performed to assess if the available information is sufficient to reject this association. Twelve trials met the study criteria, with a total of 36, 397 patients. GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.06; 95% CI 0.67 to 1.67; I2 14%). TSA confirmed that enough patients were randomized and again no association of the medications and pancreatic cancer was observed considering a NNH of 1000 and the short mean follow-up of the included trials (1.7 years). Larger studies with longer duration would be required to exclude a greater NNH and to aside concerns regarding possible influence of study duration and the outcome.

PubMed Disclaimer

Conflict of interest statement

J.L.G. reports grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), during the conduct of the study; the sponsor had no interference on data extracting, analyses and manuscript writing. L.C.P., D.V.R., S.S.B. and C.B.L. have declared that no competing interests exist.

Figures

Figure 1
Figure 1
Study Flowchart.
Figure 2
Figure 2
Forest Plot for pancreatic cancer in GLP1 analogs vs. control.
Figure 3
Figure 3
TSA for pancreatic cancer.
See this image and copyright information in PMC

References

    1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165. doi: 10.1016/j.cmet.2006.01.004. - DOI - PubMed
    1. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141:4600–4605. doi: 10.1210/endo.141.12.7806. - DOI - PubMed
    1. Matveyenko AV, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes. 2009;58:1604–1615. doi: 10.2337/db09-0058. - DOI - PMC - PubMed
    1. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–156. doi: 10.1053/j.gastro.2011.02.018. - DOI - PMC - PubMed
    1. Administration, F. a. D. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes, https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm (2016).

Publication types

MeSH terms

Substances